nVerses Capital LLC Acquires 9,400 Shares of Pfizer Inc. (NYSE:PFE)

nVerses Capital LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 154.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,500 shares of the biopharmaceutical company’s stock after purchasing an additional 9,400 shares during the quarter. nVerses Capital LLC’s holdings in Pfizer were worth $449,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $34,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

PFE stock opened at $29.28 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $29.05 and its two-hundred day simple moving average is $28.42. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $32.68. The firm has a market cap of $165.89 billion, a price-to-earnings ratio of -487.92, a PEG ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.74%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is -2,800.00%.

Analysts Set New Price Targets

PFE has been the topic of several recent research reports. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Thursday, October 3rd. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.